bioRxivCancer BiologyPreprint
A paracrine circuit of IL-1b/IL-1R1 between myeloid and tumor cells drives glioblastoma progression
Z. Chen, B. Giotti, M. Kaluzova, C. Herting, G. Pinero, m. p. vallcorba, S. Cristea, J. L. Ross, J. Ackley, V. Maximov, F. Szulzewsky, M. Marquez-Ropero, A. Angione, N. Nichols, N. Tsankkova, F. Michor, D. M. Shayakhmetov, D. H. Gutmann, A. M. Tsankov, D. Hambardzumyan
Abstract
Monocytes and monocyte-derived macrophages (MDM) from blood circulation infiltrate and promote glioblastoma growth. Here we discover that glioma cells induce the expression of potent pro-inflammatory cytokine IL-1{beta} in MDM, which engages IL-1R1 in glioma cells, activates NF-{kappa}B pathway, and subsequently leads to the induction of monocyte chemoattractant proteins (MCPs). Thus, a feedforward paracrine circuit of IL-1{beta}/IL-1R1 between the tumors and MDM creates an interdependence driving glioblastoma progression. Locally antagonizing IL-1{beta}/IL-1R1 leads to reduced MDM infiltration, diminished tumor growth, reduced exhausted CD8+ T cells, and thereby extends the survival of tumor-bearing mice. In contrast to IL-1{beta}, IL-1a exhibits anti-tumor effects. Genetic deletion of Il1a is associated with decreased recruitment of lymphoid cells and loss of interferon (IFN) signaling in various immune populations and subsets of malignant cells. IL-1{beta} antagonism of IL-1{beta} should be considered as an effective anti-glioblastoma therapy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/486888v1_ufig1.gif" ALT="Figure 1"> View larger version (66K): org.highwire.dtl.DTLVardef@1c99e57org.highwire.dtl.DTLVardef@1ba9d24org.highwire.dtl.DTLVardef@a2c418org.highwire.dtl.DTLVardef@1f8091c_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma
Jacob S. Young, Nam Woo Cho, … David Ronan Raleigh·Cancer ResearchPeer-reviewed·Apr 13, 2026
- Novel IRE1-dependent proinflammatory signaling controls tumor infiltration by myeloid cells.
J. Obacz, J. Archambeau, … e. chevet·bioRxiv·Jan 11, 2020
- Glioma-derived M-CSF and IL-34 license M-MDSCs to suppress CD8+ T cells in a NOS-dependent manner
Gregory Pal Takacs, Julia S. Garcia, … Jeffrey K. Harrison·CancersPeer-reviewed·Sep 1, 2024
- Intratumoral gene delivery of 4-1BBL boosts IL-12-triggered anti-glioblastoma immunity
Taral R. Lunavat, Lisa Nieland, … Koen Breyne·bioRxiv·Feb 3, 2025
- AHR agonist ITE boosted PD1 antibodys effects by inhibiting myeloid-derived cells suppressive cells in an orthotopic mouse glioma model
- The novel compensatory reciprocal interplay between neutrophils and monocytes drives cancer progression
Z. Chen, N. Soni, … D. Hambardzumyan·bioRxiv·Jul 21, 2022